New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill A504

Introduced
1/11/22  

Caption

Requires health insurers to provide coverage for epinephrine for persons aged 18 or younger.

Impact

A504 is expected to significantly impact state health insurance regulations by ensuring that all insurers, including health service and medical service corporations, are required to cover these devices. This will likely lead to an increase in the availability and use of epinephrine auto-injectors among children, potentially reducing emergency health risks associated with anaphylactic reactions. By removing previous barriers such as prior authorization, the bill aims to make life-saving treatment quicker and more straightforward for parents and guardians to obtain in urgent situations.

Summary

Assembly Bill A504 mandates that all health insurers in New Jersey provide coverage for the purchase of epinephrine auto-injector devices for covered individuals aged 18 years or younger. This bill aims to enhance the accessibility of life-saving medication for children who may suffer from severe allergic reactions. As part of this legislation, the epinephrine auto-injector devices will be available without the need for prior authorization or any utilization management requirements, effectively streamlining the process for families in need of this essential medication.

Contention

While the bill has received support for its goal of protecting children's health, there is some discussion regarding the financial implications for insurers. Questions have arisen about how this mandate might affect insurance premiums and the overall cost structure for providers. Some critics argue that while aiming to protect children, the additional cost burden associated with ensuring guaranteed coverage for these devices could lead to increased premiums for all insured individuals. This creates a potential trade-off between public health objectives and the financial viability of insurance products.

Companion Bills

No companion bills found.

Previously Filed As

NJ A1762

Requires health insurance carriers to provide coverage for persons 18 or younger with diagnosed complex medical needs.

NJ S3331

Requires health insurance carriers to provide coverage for persons 18 or younger with diagnosed complex medical needs.

NJ S2405

Requires health insurers to provide coverage for hearing aids.

NJ A1941

Requires health insurers to provide coverage for hearing aids.

NJ A4916

Requires health insurers to cover colorectal cancer screenings for covered persons aged 33 or over and covered persons under the age of 33 if deemed medically necessary.

NJ S4254

Requires health insurers to cover colorectal cancer screenings for covered persons aged 33 or over and covered persons under the age of 33 if deemed medically necessary.

NJ A996

Requires health insurers to provide coverage for testing for suspected dyslexia.

NJ S1320

Requires health insurers to provide coverage for treatment of tick-borne diseases.

NJ A3120

Requires Medicaid provide health benefits coverage, and places certain requirements on insurers and State Health Benefits Program regarding existing mandate on health benefits coverage, for certain over-the-counter contraceptives.

NJ S2998

Clarifies coverage requirements for health insurers of over-the-counter contraceptive drugs.

Similar Bills

NH HB63

Relative to the use of nasal spray to treat anaphylaxis.

DE HB466

AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO THE APPLICATION OF NASAL EPINEPHRINE.

TX SB1619

Relating to the use of an epinephrine delivery system by certain entities.

TX HB2283

Relating to the use of an epinephrine delivery device by certain entities.

WA SB5240

Concerning anaphylaxis medications in schools.

NH HB677

Relative to the possession and use of epinephrine at recreation camps, schools, and institutions of higher education.

UT HB0333

Medications in Schools Amendments

IL HB3454

EPINEPHRINE DELIVERY DEVICE